Biodesix (BDSX) Q4 and FY2025 Outlook Exceeds Estimates with $28.8M Revenue
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Source: stocktwits
- Significant Revenue Growth: Biodesix expects FY2025 revenue of $88.5 million, a 24% YoY increase, surpassing the analyst consensus estimate of $84.65 million, indicating strong performance in the lung diagnostics sector.
- Increased Test Volumes: Test volumes reached 18,000 in Q4 and 62,600 for the year, reflecting a 23% and 15% YoY increase, respectively, showcasing the company's enhanced market demand and service capabilities.
- Lung Diagnostics Contribution: The lung diagnostics segment contributed $25.2 million in Q4 and $79.2 million for the full year, representing YoY growth of 47% and 22%, highlighting the strong growth potential of this division.
- Robust Cash Flow: Biodesix ended 2025 with $19.0 million in cash and cash equivalents, a 14% increase from the previous quarter, providing solid financial support for future growth.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on BDSX
Wall Street analysts forecast BDSX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDSX is 30.00 USD with a low forecast of 20.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 10.330
Low
20.00
Averages
30.00
High
40.00
Current: 10.330
Low
20.00
Averages
30.00
High
40.00
About BDSX
Biodesix, Inc. is a diagnostic solutions company. Biodesix Diagnostic Tests, marketed as Nodify Lung Nodule Risk Assessment and IQLung Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. The Nodify Lung Nodule Risk Assessment assesses a suspicious lung nodule's risk of lung cancer to help identify the most appropriate treatment pathway. Nodify CDT and Nodify XL2 tests are marketed as Nodify Lung Nodule Risk Assessment. The Nodify CDT test is a blood-based test that detects the presence of seven autoantibodies associated with the presence of tumors. GeneStrat ddPCR, GeneStrat NGS and VeriStrat tests are marketed as part of its IQLung testing strategy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Friedland Enterprises Acquires 5% Stake in Lulu's Fashion Lounge
- Share Acquisition: Friedland Enterprises announced the acquisition of approximately 5% of the outstanding shares of Lulu's Fashion Lounge, aiming to enhance its market influence in the fashion retail sector and potentially provide greater strategic flexibility.
- Market Signal: This acquisition indicates Friedland's confidence in Lulu's future growth potential, which may attract other investors' attention, thereby increasing Lulu's market valuation and investment appeal.
- Investment Strategy: By increasing its stake, Friedland plans to exert greater influence over Lulu's decision-making, driving business development and brand strategy, further solidifying its position in the competitive fashion industry.
- Industry Consolidation: This transaction may signal a trend of consolidation in the fashion retail sector, with Friedland's move potentially inspiring other investors to pursue similar acquisitions to seek higher market share and synergies.
Continue Reading
Biodesix (BDSX) Q4 and FY2025 Outlook Exceeds Estimates with $28.8M Revenue
- Significant Revenue Growth: Biodesix expects FY2025 revenue of $88.5 million, a 24% YoY increase, surpassing the analyst consensus estimate of $84.65 million, indicating strong performance in the lung diagnostics sector.
- Increased Test Volumes: Test volumes reached 18,000 in Q4 and 62,600 for the year, reflecting a 23% and 15% YoY increase, respectively, showcasing the company's enhanced market demand and service capabilities.
- Lung Diagnostics Contribution: The lung diagnostics segment contributed $25.2 million in Q4 and $79.2 million for the full year, representing YoY growth of 47% and 22%, highlighting the strong growth potential of this division.
- Robust Cash Flow: Biodesix ended 2025 with $19.0 million in cash and cash equivalents, a 14% increase from the previous quarter, providing solid financial support for future growth.
Continue Reading